December 1, 2025Mayo Clinic ProceedingsOpen Access

Cardiovascular Toxicity of Fluoropyrimidines: What We Know

View Full Paper

Ask AI

Bookmark

Authors

NSNeehal ShuklaCleveland Clinic JHJoseph HajjCleveland Clinic MHMichel Chedid El HelouCardiac Imaging

Discussion

Member takes

Implication

This review demonstrates cardiac toxicity from fluoropyrimidines in cancer treatment, highlighting arrhythmias and myocardial infarction as significant risks.

Key Points

Cardiac toxicity encompasses arrhythmias, myocardial infarction, and cardiogenic shock.
Management typically involves discontinuation of fluoropyrimidines and use of calcium channel blockers.
Identifying cardiovascular adverse events is difficult due to varied symptoms and lack of specific biomarkers.
Current strategies for the safe use of fluoropyrimidines necessitate careful monitoring for adverse cardiovascular events.

Cite This Study

Shukla et al. (2025) studied this question.

synapsesocial.com/papers/69402a5e2d562116f2901846 https://doi.org/10.1016/j.mayocp.2025.08.019

View Full Paper

Ask AI

Bookmark

Implication

This review demonstrates cardiac toxicity from fluoropyrimidines in cancer treatment, highlighting arrhythmias and myocardial infarction as significant risks.

Cardiovascular Toxicity of Fluoropyrimidines: What We Know

Discussion

Member takes

Implication

Key Points

Cite This Study

Cardiovascular Toxicity of Fluoropyrimidines: What We Know

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider